Matinas BioPharma Holdings, Inc. (MTNB)

NYSEAMERICAN: MTNB · IEX Real-Time Price · USD
0.646
+0.010 (1.56%)
Oct 3, 2022 4:00 PM EDT - Market closed
1.56%
Market Cap 140.07M
Revenue (ttm) n/a
Net Income (ttm) -25.44M
Shares Out 216.87M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 153,948
Open 0.640
Previous Close 0.636
Day's Range 0.630 - 0.670
52-Week Range 0.490 - 1.260
Beta 2.00
Analysts Buy
Price Target 2.81 (+335.1%)
Earnings Date Nov 7, 2022

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular ... [Read more...]

Industry Biotechnology
Founded 2013
CEO Jerome Jabbour
Employees 31
Stock Exchange NYSEAMERICAN
Ticker Symbol MTNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 2.81, which is an increase of 335.05% from the latest price.

Price Target
$2.81
(335.05% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Matinas BioPharma Announces Chairman Succession Plan

Eric J. Ende, MD, MBA Appointed as Chairman, Effective October 1, 2022; Founding Chairman Herbert J. Conrad to Remain an Independent Director of the Company Eric J. Ende, MD, MBA Appointed as Chairman, ...

1 week ago - GlobeNewsWire

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)

Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raisi...

1 month ago - Zacks Investment Research

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022

1 month ago - GlobeNewsWire

Matinas BioPharma to Participate in the BTIG Biotechnology Conference

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and s...

2 months ago - GlobeNewsWire

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on Augu...

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucl...

2 months ago - GlobeNewsWire

Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 ...

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and s...

2 months ago - GlobeNewsWire

Matinas BioPharma to Present at the LD Micro Invitational XII Conference

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and sm...

4 months ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas' proprietary LNC platform technology –

4 months ago - GlobeNewsWire

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 1...

BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucl...

4 months ago - GlobeNewsWire

Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference

BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and s...

5 months ago - GlobeNewsWire

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC ...

Other symbols: BNTX
5 months ago - Benzinga

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mR...

MAINZ, Germany and BEDMINSTER, New Jersey (USA), April 11, 2022 – BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Matinas BioPharma (NYSE AMER: MTNB, “Matinas”), a clinical-stage biopharmaceutical company f...

Other symbols: BNTX
5 months ago - GlobeNewsWire

Matinas BioPharma to Present at the Needham Virtual Healthcare Conference

BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and...

5 months ago - GlobeNewsWire

Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and...

6 months ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Matinas Biopharma Holdings, Inc. (MTNB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street...

6 months ago - Zacks Investment Research

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 –

6 months ago - GlobeNewsWire

Matinas BioPharma Provides Business Update and 2022 Strategic Outlook

– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial –

8 months ago - GlobeNewsWire

Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022

Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET

8 months ago - GlobeNewsWire

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT...

– DSMB evaluated both safety and efficacy data in recommending cohort progression –

9 months ago - GlobeNewsWire

Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer

BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...

9 months ago - GlobeNewsWire

Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...

10 months ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...

10 months ago - Zacks Investment Research

Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights

– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recomm...

10 months ago - GlobeNewsWire